BeiGene (NASDAQ:BGNE) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of BeiGene (NASDAQ:BGNE) in a research report issued on Monday. The brokerage set a “hold” rating on the stock.

Other research analysts have also recently issued reports about the company. Morgan Stanley reaffirmed an “overweight” rating and set a $300.00 price objective on shares of BeiGene in a research report on Tuesday, December 3rd. TD Cowen raised their price target on shares of BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. increased their target price on shares of BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, October 22nd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.69.

BeiGene Stock Performance

The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The company has a market cap of $18.03 billion, a PE ratio of -22.42 and a beta of 0.57. The business’s 50-day simple moving average is $194.32 and its 200 day simple moving average is $188.98. BeiGene has a 52 week low of $126.97 and a 52 week high of $248.16.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm’s revenue was up 28.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.01 EPS. On average, analysts predict that BeiGene will post -5.64 EPS for the current year.

Insider Transactions at BeiGene

In related news, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $187.27, for a total transaction of $194,202,173.59. Following the sale, the director now owns 791,493 shares of the company’s stock, valued at $148,222,894.11. This represents a 56.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Xiaodong Wang sold 40,468 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total value of $7,692,966.80. The disclosure for this sale can be found here. Insiders have sold 1,119,245 shares of company stock worth $209,700,084 in the last ninety days. Insiders own 7.43% of the company’s stock.

Hedge Funds Weigh In On BeiGene

Several hedge funds have recently bought and sold shares of BGNE. Driehaus Capital Management LLC bought a new position in shares of BeiGene in the 2nd quarter valued at $1,168,000. The Manufacturers Life Insurance Company boosted its position in shares of BeiGene by 8.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 50,262 shares of the company’s stock valued at $7,171,000 after purchasing an additional 3,915 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in BeiGene by 160.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,854 shares of the company’s stock valued at $50,706,000 after buying an additional 138,978 shares during the period. Citigroup Inc. boosted its holdings in shares of BeiGene by 25.9% during the 3rd quarter. Citigroup Inc. now owns 26,312 shares of the company’s stock worth $5,907,000 after buying an additional 5,410 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its position in shares of BeiGene by 0.6% during the 3rd quarter. Baillie Gifford & Co. now owns 3,705,756 shares of the company’s stock valued at $831,979,000 after acquiring an additional 23,807 shares during the period. 48.55% of the stock is owned by institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.